Important Note
- Consider the alcohol content of the docetaxel product being used, especially when alcohol intake should be minimized or avoided; alcohol intoxication has been reported. Slowing the infusion rate may be necessary. The alcohol content per 200 mg docetaxel dose is 6.4 g (Pfizer), 5.5 g (Sandoz), 4 g (Accord, Actavis, and Sanofi [Taxotere 1-vial formulation]), 3.7 g (Hospira), 2.9 g (Sun pharmaceutical [Docefrez]), and 2 g (Sanofi [Taxotere 2-vial formulation]).
- Consider the concentration of the specific formulation of the docetaxel product being used during admixture, as the 1-vial injection concentrate (20 mg/mL) differs from the 2-vial formulation (10 mg/mL after dilution) and differs from powder for injection, 20-mg vial (20 mg/0.8 mL or 25 mg/mL after reconstitution) and 80-mg vial (24 mg/mL after reconstitution).
General Dosage Information
- Consider the alcohol content of the docetaxel product being used, especially when alcohol intake should be minimized or avoided; alcohol intoxication has been reported. Slowing the infusion rate may be necessary. The alcohol content per 200 mg docetaxel dose is 6.4 g (Pfizer), 5.5 g (Sandoz), 4 g (Accord, Actavis, and Sanofi [Taxotere 1-vial formulation]), 3.7 g (Hospira), 2.9 g (Sun pharmaceutical [Docefrez]), and 2 g (Sanofi [Taxotere 2-vial formulation]).
- Consider the concentration of the specific formulation of the docetaxel product being used during admixture, as the 1-vial injection concentrate (20 mg/mL) differs from the 2-vial formulation (10 mg/mL after dilution) and differs from powder for injection, 20-mg vial (20 mg/0.8 mL or 25 mg/mL after reconstitution) and 80-mg vial (24 mg/mL after reconstitution).
Breast cancer, Locally advanced/metastatic disease, after failure of prior chemotherapy
- 60 to 100 mg/m(2) IV over 1 hour every 3 weeks; premedicate with oral corticosteroids, such as dexamethasone 8 mg ORALLY twice daily for 3 days, starting 1 day prior to docetaxel
Breast cancer, Operable and node-positive, adjuvant treatment in combination with doxorubicin and cyclophosphamide
- 75 mg/m(2) IV over 1 hour, begin 1 hour after doxorubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2), every 3 weeks for 6 courses; premedicate with oral corticosteroids, such as dexamethasone 8 mg ORALLY twice daily for 3 days, starting 1 day prior to docetaxel administration and prophylactic granulocyte colony-stimulating factor
Gastric cancer, Advanced, in combination with cisplatin and fluorouracil
- docetaxel 75 mg/m(2) IV over 1 hour followed by cisplatin 75 mg/m(2) IV over 1 to 3 hours, both on day 1 only, followed by fluorouracil 750 mg/m(2)/day IV over 24 hours daily for 5 days (starting at the end of the cisplatin infusion); repeat every 3 weeks; premedicate docetaxel with oral corticosteroids, such as dexamethasone 8 mg ORALLY twice daily for 3 days, starting 1 day prior to docetaxel administration; premedicate cisplatin with antiemetics and appropriate hydration
Hormone refractory prostate cancer, Metastatic, in combination with prednisone
- 75 mg/m(2) IV over 1 hour every 3 weeks, administer with continuous prednisone 5 mg ORALLY twice daily; premedicate with dexamethasone 8 mg ORALLY at 12 hours, 3 hours, and 1 hour prior to docetaxel
- 50 mg/m(2) IV over 60 minutes on days 1 and 15 every 4 weeks, administer with continuous prednisolone 10 mg ORALLY daily; premedicate with dexamethasone 7.5 to 8 mg daily, starting 1 day before until 1 to 2 days after docetaxel infusions
Non-small cell lung cancer, Locally advanced/metastatic disease, as monotherapy after failure of prior platinum-based chemotherapy
- 75 mg/m(2) IV over 1 hour every 3 weeks; premedicate with dexamethasone 8 mg ORALLY twice daily for 3 days, starting 1 day prior to docetaxel administration
Non-small cell lung cancer, Unresectable, locally advanced/metastatic disease, first-line therapy in combination with cisplatin
- 75 mg/m(2) IV over 1 hour followed by cisplatin 75 mg/m(2) IV over 30 to 60 minutes every 3 weeks; premedicate with oral corticosteroids, such as dexamethasone 8 mg ORALLY twice daily for 3 days, starting 1 day prior to docetaxel administration
Ovarian cancer, First line in combination with carboplatin
- docetaxel 75 mg/m(2) IV over 1 hour followed by a 1-hour IV infusion of carboplatin AUC of 5; repeat every 3 weeks for 6 cycles
Squamous cell carcinoma of the head and neck, Locally advanced disease, induction treatment in combination with cisplatin and fluorouracil
- (induction therapy followed by radiotherapy) docetaxel 75 mg/m(2) IV over 1 hour followed by cisplatin 75 mg/m(2) IV over 1 hour, both on day 1 only, followed by fluorouracil 750 mg/m(2)/day continuous IV infusion for 5 days; repeat regimen every 3 weeks for 4 cycles; follow with radiotherapy; premedicate docetaxel with oral corticosteroids, such as dexamethasone 8 mg ORALLY twice daily for 3 days, starting 1 day prior to docetaxel administration; prophylaxis for neutropenic infections should be administered; antiemetics and appropriate hydration is required for patients receiving docetaxel in combination with cisplatin
- (induction therapy followed by chemoradiotherapy) docetaxel 75 mg/m(2) IV over 1 hour followed by cisplatin 100 mg/m(2) IV over 30 minutes to 3 hours, both on day 1 only, followed by fluorouracil 1000 mg/m(2)/day continuous IV infusion from day 1 to 4; repeat regimen every 3 weeks for 3 cycles; follow with chemoradiotherapy; premedicate docetaxel with oral corticosteroids, such as dexamethasone 8 mg ORALLY twice daily for 3 days, starting 1 day prior to docetaxel administration; prophylaxis for neutropenic infections should be administered; antiemetics and appropriate hydration is required for patients receiving docetaxel in combination with cisplatin

Docetaxel kabi 20mg/ml (Docetaxel - Concentrate for Solution for Infusion Concentrate for 20mg/ml) – Full Drug Info.

SCIENTIFIC NAME

INDICATIONS

CLASSIFICATION

MECHANISM OF ACTION

CLINICAL USE

ADULT DOSE

PEDIATRIC DOSE

ADMINISTRATION

CONTRAINDICATIONS

SIDE EFFECTS

PREGNANCY

MAJOR INTERACTIONS

MINOR INTERACTIONS

SCIENTIFIC NAME

INDICATIONS

CLASSIFICATION

MECHANISM OF ACTION

CLINICAL USE

ADULT DOSE

PEDIATRIC DOSE

ADMINISTRATION

CONTRAINDICATIONS

SIDE EFFECTS

PREGNANCY

MAJOR INTERACTIONS

MINOR INTERACTIONS